Medtechs rake in the venture cash
In terms of private investments, 2020 was the year of the liquid biopsy.
Covid or not, venture financing breaks records
Private biotechs attracted more venture cash in 2020 than in any other year of the current cycle.
Ash 2020 – Syros sets out a path to market
With funding in place, Syros is pushing its lead leukaemia project into pivotal development, and has a newly acquired second asset not far behind.
Corporate investing plays an ever bigger role in medtech
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.
Hints of moderation emerge in biotech venture funding
Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.
Cut-price drug venture takes aim at Pfizer and Astrazeneca
EQRX has closed two early-stage licensing deals to bring in small molecules that it hopes will shake up oncology pricing.
Medtech venture investors live up to their name
Fortunately for medical device start-ups, it takes more than a pandemic to put venture capitalists off doing deals.
Venture investors: biotech's preppers?
A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times.
